Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1436 • ACR Convergence 2022
Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
Mohaned Hameed¹, Sofia Exarchou¹, Anna Eberhard¹, Ankita Sharma¹, Ulf Bergström¹, Jon Einarsson² and Carl Turesson³, ¹Lund University, Malmö, Sweden, ²Skåne University Hospital, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: With increasing use of biologic disease modifying anti-rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) for the management of rheumatoid arthritis (RA), outcomes have…
Abstract Number: 1630 • ACR Convergence 2022
Single-cell Profiling of B Cell Repertoire and Gene Expression in the RA Synovium Reveals Tissue Specific Clonal Expansion
Aaron Wagner¹, Nida Meednu², Garrett Dunlap³, Fan Zhang⁴, Anna Jonsson⁵, Kevin Wei⁶, Ami Ben-artzi⁷, Lindsy Forbess⁸, Laura Geraldino-Pardilla⁹, Diane Horowitz¹⁰, Laura Hughes¹¹, Arthur Mandelin¹², Karen Salomon-Escoto¹³, Darren Tabechian¹⁴, Edward DiCarlo¹⁵, Ellen Gravallese¹⁶, Brendan Boyce¹⁷, Christopher Ritchlin¹⁸, James Lederer⁵, Mandy McGeachy¹⁹, Peter Gregersen²⁰, Paul Utz²¹, William Robinson²¹, Holden Maecker²¹, Judith James²², Joel Guthridge²², Harris Perlman²³, Joan Bathon⁹, Susan Goodman¹⁵, Gary S. Firestein²⁴, David Boyle²⁵, S. Louis Bridges, Jr.¹⁵, Kevin D Deane²⁶, V. Michael Holers²⁷, Larry Moreland²⁷, Andrew Filer²⁸, Costantino Pitzalis²⁹, Vivian Bykerk¹⁵, Laura Donlin¹⁵, Soumya Raychaudhuri⁵, Michael Brenner¹⁶, AMP RA/Lupus¹⁷, Deepak Rao⁵, Andrew McDavid¹ and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical center, Rochester, NY, ³Harvard University, Boston, MA, ⁴University of Colorado, Aurora, CO, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ⁸Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Columbia University, New York, NY, ¹⁰Northwell Health, Jericho, NY, ¹¹University of Alabama at Birmingham, Birmingham, AL, ¹²Northwestern University Feinberg School of Medicine, Chicago, IL, ¹³University of Massachusetts Medical School, Worcester, MA, ¹⁴URMC, Rochester, NY, ¹⁵Hospital for Special Surgery, New York, NY, ¹⁶Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹⁷University of Rochester, Rochester, ¹⁸Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ¹⁹University of Pittsburgh, Pittsburgh, PA, ²⁰The Feinstein Inst for Med Research, Larchmont, NY, ²¹Stanford University School of Medicine, Palo Alto, CA, ²²Oklahoma Medical Research Foundation, Oklahoma City, OK, ²³Northwestern University, Chicago, IL, ²⁴University of California, San Diego, San Diego, CA, ²⁵UCSD, La Jolla, CA, ²⁶University of Colorado Denver Anschutz Medical Campus, Denver, CO, ²⁷University of Colorado, Denver, CO, ²⁸University of Birmingham, Birmingham, United Kingdom, ²⁹Queen Mary University of London, London, United Kingdom
Background/Purpose: Ectopic lymphoid structures can develop in rheumatoid arthritis (RA) synovial tissue, but the precise pathways of B cell activation and selection are not well…
Abstract Number: 1737 • ACR Convergence 2022
In Vitro Response to Disease Modifying Antirheumatic Drugs Link Molecular Drug Target with Synovial Transcriptional Signature
Mads Brüner¹, Ulvi Ahmadov¹, Morten Aagaard Nielsen², Lasse Sommer Kristensen¹ and Tue Kragstrup³, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Biomedicine, Aarhus University, and Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Aarhus University, Aarhus, Denmark
Background/Purpose: Immune-mediated inflammatory arthritis (IMIA) is a group of diseases characterized by chronic synovitis including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA). Some…
Abstract Number: 1770 • ACR Convergence 2022
Prevalence and Incidence of Depression in Patients with Rheumatoid Arthritis: A Systematic Review
John E Oghene¹, Griffin Reed², Ian Saldanha³, Pooja Reddy⁴, Ahmed Elshazly⁵, Yuvaraj Singh⁶ and Deepan Dalal⁷, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²Rhode island hospital, Brown University Warren Alpert School of Medicine, Providence, RI, ³Brown University School of Public Health, Providence, RI, ⁴Rhode island hospital, Brown University Warren Alpert School of Medicine, Seekonk, MA, ⁵Westerly Hospital, Yale New Haven Health, Westerly, RI, ⁶Saint Vincent Hospital, Worcester, MA, ⁷Brown University School of Medicine, Providence, RI
Background/Purpose: Depression is a common co-morbidity that has been shown to worsen symptoms such as pain, fatigue, decreased functional status, decreased disease remission, and response…
Abstract Number: 1959 • ACR Convergence 2022
Increased Mortality in Patients with RA-Associated Interstitial Lung Disease: Data from a French Administrative Healthcare Database
Pierre-Antoine Juge¹, Lidwine Wemeau², Sebastien Ottaviani³, guillaume desjeux⁴, Joe Zhuo⁵, Virginie Vannier-Moreau⁶, René-Marc Flipo⁷, Bruno Crestani⁸ and Philippe Dieude⁹, ¹Rheumatology department, Bichat Hospital, Paris, France, ²Pulmonology department, Lille University hospital, Lille, France, ³Hopital Bichat-Claude Bernard, Paris, France, ⁴e-Health Services Sanoia, Gemenos, France, ⁵BMS, Lawrenceville, NJ, ⁶BMS, Rueil-Malmaison, ⁷Hôpital Roger Salengro, Lille, France, ⁸Hopital Bichat, Paris University, Paris, France, ⁹Université Paris Cité, Paris, France
Background/Purpose: Interstitial lung disease (ILD) is a common extra-articular manifestation of RA. Studies have shown variability in the prevalence and mortality rate of patients with…
Abstract Number: 1977 • ACR Convergence 2022
Tc99m Tilmanocept Imaging Predicts Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy
Jonathan Graf¹, Martin Jacobs², Debbie Gladd-Foley³, Yelliann Ruiz-Irizarry⁴, Alan Kivitz⁵, Melvin Churchill⁶, Arash Kardan⁷, Mara Leach⁸, David Ralph⁸, Nicole Korczak⁸, Addison Hasselbach⁸, Bonnie Abbruzzese⁸, Rachael Hershey⁸, Beth Potter⁸, Jessica Fitzpatrick⁸, Aaron Thornton⁸, Michael Blue⁸ and Michael Rosol⁸, ¹Ucsf, San Francisco, CA, ²Kettering Network Radiologists, Kettering, OH, ³Premier Rheumatology of Oklahoma, Tulsa, OK, ⁴Jackson Health System, Innovation Medical Research Center, Palmetto Bay, FL, ⁵Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁶Arthritis Center of Nebraska, Bryan Health, Lincoln, NE, ⁷Baylor College of Medicine, Department of Radiology, Houston, TX, ⁸Navidea Biopharmaceuticals, Dublin, OH
Background/Purpose: Effective and expeditious control of rheumatoid arthritis (RA) disease activity using a treat-to-target (T2T) strategy is crucial to prevent long term damage and disability.…
Abstract Number: 1994 • ACR Convergence 2022
Is Glucocorticoid Bridging Associated with Later Glucocorticoid and Biological DMARD Use in Patients with Rheumatoid Arthritis?
Lotte van Ouwerkerk¹, Sytske Anne Bergstra², Tjardo Maarseveen¹, Rachel Knevel¹, Tom Huizinga¹ and CF Allaart¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands
Background/Purpose: Glucocorticoids (GC) are rapidly effective in suppressing disease activity in rheumatoid arthritis (RA), and are often used as 'bridging' therapy while slower acting conventional…
Abstract Number: 2010 • ACR Convergence 2022
Lowering Expectations: Glucocorticoid Tapering Among Veterans with Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy
Beth Wallace¹, Bryant England², Joshua Baker³, Gary Kunkel⁴, Tawnie Braaten⁵, Jorge Rojas⁶, Alison Petro², Punyasha Roul⁷, Ted Mikuls⁸, Brian Sauer⁹ and Grant Cannon¹⁰, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Utah, Salt Lake City, UT, ⁵University of Utah Hospitals and Clinics and VA Salt Lake City Health Care System, Salt Lake City, UT, ⁶George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁷UNMC, Omaha, NE, ⁸Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁹Salt Lake City VA/University of Utah, Salt Lake City, UT, ¹⁰Retired, Salt Lake City, UT
Background/Purpose: Up to 80% of RA patients use glucocorticoids (GC) at some time in their illness. Current ACR guidelines note that difficulty tapering GC promotes…
Abstract Number: 2204 • ACR Convergence 2022
Interosseous Tendon Inflammation in the Hands: A Novel Feature of Developing Rheumatoid Arthritis? Results from a Large MRI Study in Clinically Suspect Arthralgia
Bastiaan van Dijk¹, Hanna van Steenbergen¹, Monique Reijnierse², Sarah J.H. Khidir², Lambertus Wisse¹, Marco deRuiter¹ and Annette van der Helm-van Mil³, ¹Leiden University Medical Centre (LUMC), Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Inflammation around the tendons of hand interosseous muscles (interosseous tendon inflammation; ITI) on MRI was recently reported for the first time in rheumatoid arthritis…
Abstract Number: PP02 • ACR Convergence 2022
Patient Mobilization for Vaccine Access and Improved Care During the COVID Pandemic
Marie-Claude Beaulieu¹, Ines Colmegna², Nathalie Amiable³, Jean Légaré⁴ and Paul Fortin⁵, ¹Universite de Sherbrooke, Sherbrooke, QC, Canada, ²The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³CHU de Québec, Quebec, QC, Canada, ⁴QC, Canada, ⁵CHU de Quebec - Universite Laval, Quebec, QC, Canada
Background/Purpose: The COVID pandemic was particularly difficult for persons like me living with rheumatoid arthritis and immunosuppressed. I had to impose myself months of isolation…
Abstract Number: 0069 • ACR Convergence 2022
Capturing Clinical Reasoning in Real Time Reveals Low Rate of Serious Adverse Reactions Requiring B/tsDMARD Discontinuation in Inflammatory Joint Disease: An Analysis of the OPAL Real-World Dataset
Geoffrey Littlejohn¹, Tegan Smith², Sabina Ciciriello³, Peter Youssef⁴, Claire Deakin⁵, Nithila Anbumurali⁶ and Catherine OSullivan⁶, ¹OPAL Rheumatology Ltd, Melbourne, Australia, ²OPAL Rheumatology Ltd, Geelong, Australia, ³Melbourne Health, Melbourne, Australia, ⁴University of Sydney, Sydney, Australia, ⁵OPAL Rheumatology Ltd, Mosman, Australia, ⁶OPAL Rheumatology Ltd, Sydney, Australia
Background/Purpose: Routine management of inflammatory joint disease requires clinicians to consider an abundance of factors unique to each patient when deciding on the most appropriate…
Abstract Number: 0181 • ACR Convergence 2022
Patient Perspective of Unique Support and Education Needs of Latinx/Latino(a)/Hispanic Rheumatoid Arthritis Patients: Implications for a Culturally Tailored and Disease Specific Intervention
Anna Balakrishnan¹, Adena Batterman¹, Daniel Hernandez², Angel Tapia³, Joan Westreich¹, Roberta Horton¹ and Theodore Fields¹, ¹Hospital for Special Surgery, New York, NY, ²Global Healthy Living Foundation, Nyack, NY, ³Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose: Health disparities for Latinx RA patients, including higher pain, fatigue, disability, and risk for depression are well documented.1, 2, 3, 4 Support and education…
Abstract Number: 0246 • ACR Convergence 2022
Comorbidity Clusters in Patients with Rheumatoid Arthritis Predict Survival Prognosis
Cynthia Crowson¹, Tina Gunderson², John Davis², Elena Myasoedova², Vanessa Kronzer², Caitrin Coffey², Bradly Kimbrough³ and Elizabeth Atkinson², ¹Mayo Clinic, Eyota, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic Rochester, Rochester, MN
Background/Purpose: Comorbidities are common in patients with rheumatoid arthritis (RA), but there is little information regarding the occurrence of distinct comorbidity patterns in patients with…
Abstract Number: 0262 • ACR Convergence 2022
Predictors of Fragility Fracture Amongst Patients with Rheumatoid Arthritis: An Observational Cohort Study
Seema Sharma¹ and Marwan Bukhari², ¹Lancaster Royal Infirmary, Lancaster, United Kingdom, ²University Hospitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is associated with reduced bone mineral density and almost one third of this population have osteoporosis leading to increased risk of…
Abstract Number: 0279 • ACR Convergence 2022
Effect of Filgotinib on Body Weight and BMI and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in RA
Alejandro Balsa¹, Siegfried Wassenberg², Anne Tournadre³, Hans-Dieter Orzechowski⁴, Katrien Van Beneden⁵, Vijay Rajendran⁶, Udo Lendl⁴, Pieter-Jan Stiers⁵, Christopher Watson⁷, Roberto Felice Caporali⁸ and Patrick Verschueren⁹, ¹Hospital La Paz Institute for Health Research, Madrid, Spain, ²Rheumazentrum Ratingen, Ratingen, Germany, ³University Hospital of Clermont Ferrand, Rheumatology, Clermont-Ferrand, France, ⁴Galapagos Biopharma Deutschland GmbH, Munich, Germany, ⁵Galapagos NV, Mechelen, Belgium, ⁶Galapagos NV, Gent, Belgium, ⁷Galapagos Biotech Ltd, Cambridge, United Kingdom, ⁸University of Milan, Milano, Italy, ⁹University Hospital Leuven, Leuven, Belgium
Background/Purpose: Filgotinib (FIL) is a Janus kinase (JAK) 1 preferential inhibitor approved for the treatment (tx) of moderate to severe RA. Weight gain has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].